Daniel Janney sold $16M of KRYS
director at Krystal Biotech, Inc.. 60,161 shares at an average of $268.44, traded Feb 24, 2026, filed Feb 26, 2026.
Score components
- +15RoleDirector
- +25Trade size$16.1M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.2%, 3m +12.3%, 6m +29.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001711279-26-000021, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | MOption exercise Common Stock10b5-1 | +37,895 | $2.46 | $93k | 37,895 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -569 | $262.91 | $150k | 37,326 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -1,733 | $264.12 | $458k | 35,593 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -3,557 | $265.08 | $943k | 32,036 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -8,986 | $266.18 | $2.4M | 23,050 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -11,673 | $266.97 | $3.1M | 11,377 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -6,671 | $268.04 | $1.8M | 4,706 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -3,963 | $268.97 | $1.1M | 743 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -370 | $269.83 | $100k | 373 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stock10b5-1 | -373 | $271.09 | $101k | 0 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -62 | $263.05 | $16k | 107,300 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -900 | $264.60 | $238k | 106,400 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -1,604 | $265.54 | $426k | 104,796 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -4,339 | $266.62 | $1.2M | 100,457 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -1,891 | $267.37 | $506k | 98,566 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -1,674 | $268.67 | $450k | 96,892 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -930 | $269.50 | $251k | 95,962 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -2,425 | $274.90 | $667k | 93,537 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -700 | $275.00 | $193k | 92,837 | Feb 26, 2026 |
| Feb 26, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -5,103 | $275.28 | $1.4M | 87,734 | Feb 26, 2026 |
| Feb 26, 2026 | SOpen-market sale Common Stockindirect: Directly beneficially owned by Alta Bioequities, L.P.10b5-1 | -2,638 | $276.32 | $729k | 85,096 | Feb 26, 2026 |
| Feb 24, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -37,895 | $0.00 | $0 | 0 | Feb 26, 2026 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 50Moderate | KRYSsell Krystal Biotech, Inc. | Dino A Rossi director | $8.2M 25,000 shares | -33% | |
| 15Weak | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $347k 1,000 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $7.7M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $7.7M 25,000 shares | -2% | |
| 42Moderate | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $194k 642 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Daniel Janney director | $3.3M 11,803 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.